Free Trial
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

NewAmsterdam Pharma logo
$23.37 -0.21 (-0.89%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$23.38 +0.01 (+0.04%)
As of 03/14/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

Key Stats

Today's Range
$22.76
$24.00
50-Day Range
$17.53
$26.04
52-Week Range
$15.19
$27.29
Volume
1.38 million shs
Average Volume
487,946 shs
Market Capitalization
$2.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.33
Consensus Rating
Buy

Company Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Remove Ads

NewAmsterdam Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

NAMS MarketRank™: 

NewAmsterdam Pharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 485th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NewAmsterdam Pharma has only been the subject of 4 research reports in the past 90 days.

  • Read more about NewAmsterdam Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NewAmsterdam Pharma is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NewAmsterdam Pharma is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NewAmsterdam Pharma has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about NewAmsterdam Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    5.37% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NewAmsterdam Pharma has recently increased by 4.47%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    NewAmsterdam Pharma does not currently pay a dividend.

  • Dividend Growth

    NewAmsterdam Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.37% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NewAmsterdam Pharma has recently increased by 4.47%, indicating that investor sentiment is decreasing.
  • News Sentiment

    NewAmsterdam Pharma has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for NewAmsterdam Pharma this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NewAmsterdam Pharma insiders have sold 10,865.45% more of their company's stock than they have bought. Specifically, they have bought $84,185.00 in company stock and sold $9,231,268.00 in company stock.

  • Percentage Held by Insiders

    19.50% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NewAmsterdam Pharma's insider trading history.
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

NAMS Stock News Headlines

NewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper Sandler
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.
See More Headlines

NAMS Stock Analysis - Frequently Asked Questions

NewAmsterdam Pharma's stock was trading at $25.70 at the beginning of 2025. Since then, NAMS stock has decreased by 9.1% and is now trading at $23.37.
View the best growth stocks for 2025 here
.

NewAmsterdam Pharma (NASDAQ:NAMS) released its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.47. The firm earned $12.77 million during the quarter, compared to analyst estimates of $3.30 million.

Top institutional investors of NewAmsterdam Pharma include Frazier Life Sciences Management L.P. (17.23%), Bain Capital Life Sciences Investors LLC (11.60%), Fcpm Iii Services B.V. (11.47%) and RA Capital Management L.P. (9.57%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Louis G Lange, Louise Frederika Kooij, Juliette Berangere Audet and Johannes Jacob Piete Kastelein.
View institutional ownership trends
.

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), PIMCO Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

Last Earnings
2/26/2025
Today
3/14/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NAMS
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.33
High Stock Price Target
$52.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+85.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$45.56 million
Price / Cash Flow
N/A
Book Value
$3.50 per share
Price / Book
6.68

Miscellaneous

Free Float
74,371,000
Market Cap
$2.57 billion
Optionable
Optionable
Beta
-0.04
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:NAMS) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners